Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate
Hanmi Pharm, a South Korean pharmaceutical company, signed a 3.2 trillion won licensing deal with Roche's Genentech for an obesity drug candidate. This marks a significant deal in the pharmaceutical industry with implications for obesity treatment development.
Hanmi Pharm Roche Genentech licensing deal obesity drug